PL2489731T3 - Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol - Google Patents

Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol

Info

Publication number
PL2489731T3
PL2489731T3 PL12003811T PL12003811T PL2489731T3 PL 2489731 T3 PL2489731 T3 PL 2489731T3 PL 12003811 T PL12003811 T PL 12003811T PL 12003811 T PL12003811 T PL 12003811T PL 2489731 T3 PL2489731 T3 PL 2489731T3
Authority
PL
Poland
Prior art keywords
cholesterol acyltransferase
modified lecithin
acyltransferase enzymes
enzymes
lecithin
Prior art date
Application number
PL12003811T
Other languages
English (en)
Inventor
Mingyue Zhou
Thomas Charles Boone
David Park Meininger
Margit Schwarz
Bei Shan
Wenyan Shen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PL2489731T3 publication Critical patent/PL2489731T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PL12003811T 2007-07-26 2008-07-25 Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol PL2489731T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95200707P 2007-07-26 2007-07-26
EP20080796592 EP2181190B1 (en) 2007-07-26 2008-07-25 Modified lecithin-cholesterol acyltransferase enzymes
EP20120003811 EP2489731B1 (en) 2007-07-26 2008-07-25 Modified lecithin-cholesterol acyltransferase enzymes

Publications (1)

Publication Number Publication Date
PL2489731T3 true PL2489731T3 (pl) 2015-01-30

Family

ID=39864722

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08796592T PL2181190T3 (pl) 2007-07-26 2008-07-25 Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol
PL12003811T PL2489731T3 (pl) 2007-07-26 2008-07-25 Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08796592T PL2181190T3 (pl) 2007-07-26 2008-07-25 Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol

Country Status (25)

Country Link
US (3) US8168416B2 (pl)
EP (4) EP2489731B1 (pl)
JP (5) JP5643643B2 (pl)
KR (1) KR20100040937A (pl)
CN (1) CN101855344B (pl)
AU (1) AU2008279065B2 (pl)
BR (1) BRPI0814310A2 (pl)
CA (1) CA2694590A1 (pl)
CR (1) CR11272A (pl)
CY (2) CY1114857T1 (pl)
DK (2) DK2489731T3 (pl)
EA (1) EA201070187A1 (pl)
ES (3) ES2449483T3 (pl)
HR (1) HRP20140315T1 (pl)
IL (1) IL203399A0 (pl)
MX (1) MX348799B (pl)
MY (1) MY159075A (pl)
NZ (2) NZ582794A (pl)
PL (2) PL2181190T3 (pl)
PT (2) PT2181190E (pl)
RS (1) RS53237B (pl)
SG (1) SG186016A1 (pl)
SI (2) SI2489731T1 (pl)
UA (1) UA103304C2 (pl)
WO (1) WO2009015314A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2489731T1 (sl) * 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze
CN102802659B (zh) * 2009-06-12 2015-11-25 阿尔法科制药有限责任公司 Lcat治疗贫血和红细胞功能障碍的用途
BR112012028462A2 (pt) * 2010-05-06 2016-07-19 Alphacore Pharma Llc liberação de éster de colesterol para tecidos esteroidogênicos
EP2701732B1 (en) * 2011-02-25 2017-08-30 University Of Patras Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld)
SG194780A1 (en) * 2011-05-05 2013-12-30 Wellstat Immunotherapeutics Llc Complement factor b analogs and their uses
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US10583104B2 (en) * 2014-08-06 2020-03-10 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
US20180265885A1 (en) * 2015-01-29 2018-09-20 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
US20200261549A1 (en) * 2017-11-07 2020-08-20 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
EA202092799A1 (ru) 2018-05-22 2021-03-01 ДСМ АйПи АССЕТС Б.В. Модифицированные стерол-ацилтрансферазы
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
US12544402B2 (en) 2020-02-28 2026-02-10 Repair Biotechnologies, Inc. Targeted expression of microbial cholesterol catalysis genes reduces excess lipid

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63167409A (ja) 1986-12-27 1988-07-11 Yamaha Corp 磁気記録体
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
BR9609872A (pt) 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
CA2236982C (en) * 1995-11-09 2010-07-27 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
EP0973914B1 (en) * 1997-04-11 2006-12-13 Takeda Pharmaceutical Company Limited Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001005943A2 (en) 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
SI2489731T1 (sl) * 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze

Also Published As

Publication number Publication date
NZ597885A (en) 2013-08-30
US8168416B2 (en) 2012-05-01
CY1115573T1 (el) 2017-01-04
EP2522721B1 (en) 2016-05-04
WO2009015314A2 (en) 2009-01-29
HRP20140315T1 (hr) 2014-05-09
EP2489730A1 (en) 2012-08-22
US9006408B2 (en) 2015-04-14
PT2489731E (pt) 2014-09-15
MX348799B (es) 2017-06-29
HK1138039A1 (en) 2010-08-13
UA103304C2 (ru) 2013-10-10
CN101855344B (zh) 2015-12-09
EP2489731A1 (en) 2012-08-22
EP2489730B1 (en) 2015-12-30
CN101855344A (zh) 2010-10-06
DK2181190T3 (da) 2014-03-31
CA2694590A1 (en) 2009-01-29
DK2489731T3 (en) 2014-11-17
JP2016182136A (ja) 2016-10-20
PT2181190E (pt) 2014-02-24
JP6033258B2 (ja) 2016-11-30
CR11272A (es) 2010-05-26
SI2181190T1 (sl) 2014-04-30
CY1114857T1 (el) 2016-12-14
KR20100040937A (ko) 2010-04-21
JP2018161134A (ja) 2018-10-18
EA201070187A1 (ru) 2010-08-30
JP5643643B2 (ja) 2014-12-17
IL203399A0 (en) 2011-07-31
SI2489731T1 (sl) 2014-12-31
US8703926B1 (en) 2014-04-22
AU2008279065A1 (en) 2009-01-29
WO2009015314A3 (en) 2009-03-12
EP2489731B1 (en) 2014-08-27
AU2008279065B2 (en) 2013-12-12
EP2522721A2 (en) 2012-11-14
JP2014198047A (ja) 2014-10-23
ES2513716T3 (es) 2014-10-27
MY159075A (en) 2016-12-15
JP2010534479A (ja) 2010-11-11
EP2181190A2 (en) 2010-05-05
RS53237B (sr) 2014-08-29
US20090081182A1 (en) 2009-03-26
EP2181190B1 (en) 2014-01-08
ES2559353T3 (es) 2016-02-11
NZ582794A (en) 2012-09-28
EP2522721A3 (en) 2013-01-23
US20140287479A1 (en) 2014-09-25
PL2181190T3 (pl) 2014-06-30
ES2449483T3 (es) 2014-03-19
BRPI0814310A2 (pt) 2015-01-06
SG186016A1 (en) 2012-12-28
JP2020058366A (ja) 2020-04-16

Similar Documents

Publication Publication Date Title
SI2181190T1 (sl) Modificirani encimi lecitin-holesterol aciltransferaze
GB0719620D0 (en) Mutant Enzymes
PL2155866T3 (pl) Modyfikowane fosfatazy
EP2197893A4 (en) NEW MUSHROOM CYMS
IL212496A0 (en) Diacylglycerol acyltransferase inhibitors
PL2017352T3 (pl) Sensor elektrochemiczny z kowalencyjnie związanym enzymem
ZA200808672B (en) Bioreactor
PL2092051T3 (pl) Fermentor
IL191851A0 (en) Universal insert
GB0804721D0 (en) Enzyme
GB0613603D0 (en) Insert
GB0818328D0 (en) Novel enzyme
GB0803628D0 (en) Enzyme
GB0716702D0 (en) Enzyme productions
IL207848A0 (en) Artificial enzymes
GB0804722D0 (en) Enzyme
GB0800831D0 (en) Enzymes 1
GB2467284B (en) Sulfatase enzymes
GB0716735D0 (en) Insert stove
GB0711245D0 (en) Enzyme
GB0713609D0 (en) Enzyme
GB0711246D0 (en) Enzyme
GB0713610D0 (en) Enzyme
GB0617387D0 (en) Synthetic gene
HU0600159D0 (en) Kvantitative pcr